Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 4/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.38 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.38 |
| ▸ | PSAT1 | Q9Y617 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7592170 | 0.89 | LNPEP (0.53) | PPARGPPARDPPARAPOLBLNPEP | |
| SCHEMBL7594870 | 0.81 | ALDH1A1 (0.41) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL6168965 | 0.75 | RAB9A (0.48) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL7916874 | 0.74 | HCAR3 (0.59) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL7593521 | 0.74 | ALDH1A1 (0.47) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL7593566 | 0.73 | KMT2A (0.46) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL27879474 | 0.71 | HCAR3 (0.55) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL7597821 | 0.71 | MME (0.44) | LTB4RALDH1A1LNPEPMEN1KMT2A | |
| SCHEMBL7596215 | 0.70 | ALDH1A1 (0.51) | LTB4RALDH1A1LMNAPOLBMEN1 | |
| SCHEMBL7594893 | 0.69 | LTB4R2 (0.42) | LTB4RALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | OSI PHARMACEUTICALS, INC. | 2002-06-27 | — | — | US | disclosed |
| US-6348032-B1 | POTENT COMPOUNDS THAT INDUCE APOPTOSIS IN NEOPLASTIC CELLS (BUT NOT SUBSTANTIALLY IN NORMAL CELLS), WITHOUT SUBSTANTIALLY INHIBITING PGE-2. | CELL PATHWAYS, INC. | 2002-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | MKI67, CCNI, TMBIM6 | LTB4R 1803/4885PPARG 1181/4885PPARD 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.